| Literature DB >> 32423014 |
Wen Li1,2, Ming Xi Jia1, Jing Deng1,2, Jian Hui Wang3, Zavuga Zuberi2,4, Sheng Yang5, Jie Ba1, Zhu Chen2.
Abstract
Titanium dioxide nanoparticles (TiO2-NPs) are widely used for biomedical and food applications, the toxicity of TiO2-NPs in vivo and in vitro has been elucidated, but the underlying cytotoxicity of TiO2-NPs against microRNA remains largely unknown. The purpose of this study was to analyze microRNA profiling induced by TiO2-NPs against NCM460 and HCT116 cell lines. Comparative analysis identified 34 and 24 microRNAs were significantly altered in the TiO2-NPs treated cells at concentrations of 3 and 30 μg/mL, respectively. Functional classification demonstrated that a large proportion of genes involved in metabolism, human disease, and environmental information process were significantly upregulated by TiO2-NPs. Bioinformatics analysis suggested that microRNA 378 might be an early indicator of cellular response to exogenous stimuli with apoptotic signals. Furthermore, TiO2-NPs significantly altered the expression of microRNA 378b and 378g in HCT116 and NCM460 cell lines at different concentrations from 3 to 6 μg/mL. These concentrations elicit high-sensitivity of stimuli response in colon cancer cells when exposed to the slight doses of TiO2-NPs. Our study indicated that microRNAs 378b and 378g may play an important role in TiO2-NPs-mediated colonic cytotoxicity, which may provide a valuable insight into the molecular mechanisms of potential risks in colitis and colon cancer.Entities:
Keywords: TiO2-NPs; bioinformatics analysis; cytotoxicity; human colon cancer cell
Year: 2020 PMID: 32423014 PMCID: PMC7281448 DOI: 10.3390/cancers12051236
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
List of microRNA reverse transcriptional stem-loop primer sequences.
| Gene Name | Loop-RT Primer Sequence |
|---|---|
| Homo U6 | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATA |
| hsa-miR-378b | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTTCTGC |
| hsa-miR-378g | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTTCTG |
List of upstream and downstream primer sequences.
| Primer Name | Sequence (5′–3′) |
|---|---|
| Homo U6 Forward primer | AGAGAAGATTAGCATGGCCCCTG |
| hsa-miR-378b Forward primer | GCGCGACTGGACTTGGAG |
| hsa-miR-378g Forward primer | CGCGACTGGGCTTGGAGT |
| General Reverse primer | AGTGCAGGGTCCGAGGTATT |
Figure 1Characterization of nanomaterials. (a) XRD pattern of titanium dioxide nanoparticles (TiO2-NPs); (b) TEM image of TiO2-NPs.
Figure 2Cytotoxicity of TiO2-NPs against HCT116 and NCM460 cell lines. The experiments were carried out in triplicate and data presented are in mean values. * indicates p < 0.05.
Figure 3TiO2-NPs induces oxidative stress. The cells were treated with 3 to 60 μg/mL of titanium dioxide NPs within 24 h. The experiments were carried out in triplicate and data presented are in mean values, * indicates p < 0.05, ** indicates p < 0.01.
Alignment statistics of tags align to reference genome.
| Sample Name | Total Tag | Mapped Tag | Percentage (%) |
|---|---|---|---|
| control | 34,995,302 | 29,921,249 | 85.50 |
| TiO2-NPs-3 μg/mL | 34,231,512 | 28,095,346 | 82.07 |
| TiO2-NPs-30 μg/mL | 39,190,347 | 30,681,926 | 78.29 |
Figure 4Proportion of small RNAs among different categories. To make every unique small RNA mapped to only one annotation, we follow the following priority rule: microRNA > piRNA > snRNA > Rfam > other RNAs. (a) Pie diagram for annotation of small RNA in control HCT116 cell lines (total for each category); (b) Pie diagram for annotation of small RNA in TiO2-NPs-3μg/mL treated HCT116 cell lines (total for each category); (c) Pie diagram for annotation of small RNA in TiO2-30 μg/mL treated HCT116 cell lines (total for each category).
Figure 5Graph of statistical numbers of differentially expressed microRNA. X-axis represents each pair of differential alignment schemes, and Y-axis represents the corresponding number of differential microRNAs. A vs B means sample B is the control and sample A is the case. If a gene is upregulated it means the expression of this gene is upregulated in sample A compared to sample B.
List of total microRNAs significantly regulated by TiO2-NPs. The fold change was the log2-Ratio value, cut-off at log2-Ratio ≥ 1 or log2Ratio ≤ −1.
| TiO2-NPs-3μg/mL | Fold Change | TiO2-NPs-30μg/mL | Fold Change |
|---|---|---|---|
| hsa-miR-378f | 3.520946008 | hsa-miR-378e | 4.722807531 |
| hsa-miR-103a-3p | 2.953306765 | hsa-miR-199b-3p | 3.924812504 |
| hsa-miR-27b-5p | 2.214124805 | hsa-miR-4443 | 2.025090981 |
| hsa-miR-4443 | 2.201674124 | hsa-miR-101-3p | 1.893084796 |
| hsa-miR-378g | 2.175707743 | hsa-miR-1307-5p | 1.620411337 |
| hsa-miR-374c-3p | 1.415037499 | hsa-miR-378b | 1.61172941 |
| hsa-miR-378i | −4.07681560 | hsa-miR-103a-3p | 1.463602466 |
| hsa-miR-374b-5p | −3.824842349 | hsa-miR-210-3p | 1.429585808 |
| hsa-miR-4284 | −3.148259549 | hsa-miR-193b-3p | 1.180827839 |
| hsa-let-7f-2-3p | −2.626782676 | hsa-miR-629-5p | 1.152003093 |
| hsa-miR-501-5p | −2.163975735 | hsa-miR-339-3p | 1.025943267 |
| hsa-miR-24-3p | −2.138268765 | hsa-miR-199a-3p | −7.105035471 |
| hsa-miR-3656 | −2.080703096 | hsa-miR-378i | −6.169925001 |
| hsa-miR-3074-5p | −1.826741314 | hsa-miR-378g | −3.798524718 |
| hsa-miR-132-3p | −1.712341807 | hsa-miR-548ae-5p | −3.321928095 |
| hsa-miR-339-5p | −1.656663966 | hsa-miR-374b-5p | −3.228198043 |
| hsa-miR-3960 | −1.506687086 | hsa-miR-4284 | −1.982249598 |
| hsa-miR-6821-5p | −1.436099115 | hsa-miR-132-3p | −1.712341807 |
| hsa-miR-7704 | −1.395592382 | hsa-miR-1246 | −1.695664562 |
| hsa-miR-143-3p | −1.358520148 | hsa-miR-339-5p | −1.5334322 |
| hsa-let-7a-3p | −1.311523999 | hsa-miR-24-3p | −1.389680675 |
| hsa-miR-135b-5p | −1.300942024 | hsa-miR-1290 | −1.253756592 |
| hsa-miR-5701 | −1.247461602 | hsa-miR-143-3p | −1.130466392 |
| hsa-miR-148b-3p | −1.235501962 | hsa-miR-5701 | −1.003732719 |
| hsa-miR-1290 | −1.208769137 | ||
| hsa-miR-29b-3p | −1.198023321 | ||
| hsa-miR-96-5p | −1.168774188 | ||
| hsa-miR-103b | −1.141661149 | ||
| hsa-miR-128-3p | −1.132807408 | ||
| hsa-miR-4532 | −1.114263111 | ||
| hsa-let-7i-3p | −1.101879614 | ||
| hsa-miR-33b-3p | −1.091524104 | ||
| hsa-miR-151b | −1.032454631 |
Figure 6GO classification map of target genes of differential microRNAs. (a) 3 μg/mL group VS control group; (b). 30 μg/mL group VS control group. X-axis represents number of DEGs (the number is presented by its square root value), Y-axis represents GO terms. All GO terms are grouped into three ontologies: blue is for biological processes, brown is for cellular component, and orange is for molecular function.
Altered canonical pathways by TiO2-NPs in HCT116 cells.
| TiO2-NPs-3 μg/mL | TiO2-NPs-30 μg/mL |
|---|---|
| Thiamine metabolism | Thiamine metabolism |
| Purine metabolism | Purine metabolism |
| Glycosaminoglycan biosynthesis—chondroitin sulfate/dermatan sulfate | Transcriptional misregulation in cancer |
| Glycosaminoglycan biosynthesis—heparan sulfate/heparin | Metabolic pathways |
| Transcriptional misregulation in cancer | Glycosaminoglycan biosynthesis—chondroitin sulfate/dermatan sulfate |
| Metabolic pathways | Glycosaminoglycan biosynthesis—heparan sulfate/heparin |
| Notch signaling pathway | Phosphatidylinositol signaling system |
| ECM-receptor interaction | Notch signaling pathway |
| Vibrio cholerae infection | Endocytosis |
| Lysine degradation | Breast cancer |
| Amoebiasis | Lysine degradation |
| Hedgehog signaling pathway | N-Glycan biosynthesis |
| Axon guidance | Hippo signaling pathway—multiple species |
| cAMP pathway | Signaling pathways regulating pluripotency of stem cells |
| Gap junction | cAMP pathway |
| MicroRNAs in cancer | |
| Prion diseases | |
| mTOR signaling pathway | |
| MAPK/ERK pathway |
Figure 7The KEGG pathway annotation classification chart of the differential microRNA target gene. (a) 3 μg/mL group VS control group; (b) 30 μg/mL group VS control group. The abscissa is the number of target genes that differ in small RNA, and the ordinate represents the secondary KEGG pathway. The secondary pathways belong to different primary pathways, respectively, and different levels represent the first-level communication categories.
List of predicted microRNA 378b target gene.
| Target Gene | Gene Name | Cumulative Weighted Context++ Score |
|---|---|---|
| GOLT1A | golgi transport 1A | −0.59 |
| SBDS | Shwachman–Bodian–Diamond syndrome | −0.47 |
| EIF4G3 | eukaryotic translation initiation factor 4 gamma, 3 | −0.47 |
| KIAA1522 | KIAA1522 | −0.46 |
| VANGL1 | VANGL planar cell polarity protein 1 | −0.46 |
| ZFP36L2 | ZFP36 ring finger protein-like 2 | −0.39 |
| PTPRT | protein tyrosine phosphatase, receptor type, T | −0.36 |
| TOB2 | transducer of ERBB2, 2 | −0.34 |
| ATG12 | autophagy related 12 | −0.32 |
| MAPK1 | mitogen-activated protein kinase 1 | −0.31 |
| DACT1 | dishevelled-binding antagonist of beta-catenin 1 | −0.31 |
| KIF2A | kinesin heavy chain member 2A | −0.31 |
| VAT1L | vesicle amine transport 1-like | −0.29 |
| RBMS1 | RNA binding motif, single-stranded interacting protein 1 | −0.29 |
| SAMD1 | sterile alpha motif domain containing 1 | −0.27 |
| SCAMP2 | secretory carrier membrane protein 2 | −0.27 |
| RNF144B | ring finger protein 144B | −0.26 |
| PIWIL2 | piwi-like RNA-mediated gene silencing 2 | −0.25 |
| ZDHHC9 | zinc finger, DHHC-type containing 9 | −0.22 |
| SUFU | suppressor of fused homolog (Drosophila) | −0.22 |
| GSTM4 | glutathione S-transferase mu 4 | −0.20 |
| CSNK1G2 | casein kinase 1, gamma 2 | −0.20 |
| UBQLN4 | ubiquilin 4 | −0.19 |
| ALPK3 | alpha-kinase 3 | −0.18 |
| CTDP1 | CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 | −0.17 |
| DYNC1LI2 | dynein, cytoplasmic 1, light intermediate chain 2 | −0.17 |
| WDR37 | WD repeat domain 37 | −0.17 |
| IGF1R | insulin-like growth factor 1 receptor | −0.16 |
| ZKSCAN1 | zinc finger with KRAB and SCAN domains 1 | −0.15 |
| CADM4 | cell adhesion molecule 4 | −0.15 |
| FCRLB | Fc receptor-like B | −0.15 |
| CUEDC1 | CUE domain containing 1 | −0.14 |
| PHF15 | PHD finger protein 15 | −0.14 |
List of predicted microRNA 378g target gene.
| Target Gene | Gene Name | Cumulative Weighted Context++ Score |
|---|---|---|
| STARD9 | StAR-related lipid transfer (START) domain containing 9 | −1.01 |
| AKAP13 | A kinase (PRKA) anchor protein 13 | −0.88 |
| TMEM91 | transmembrane protein 91 | −0.88 |
| ADM2 | adrenomedullin 2 | −0.88 |
| HMHB1 | histocompatibility (minor) HB-1 | −0.84 |
| MYL12B | myosin, light chain 12B, regulatory | −0.79 |
| GP9 | glycoprotein IX (platelet) | −0.78 |
| NDUFA4L2 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 | −0.78 |
| GRAPL | GRB2-related adaptor protein-like | −0.78 |
| DAD1 | defender against cell death 1 | −0.75 |
| SLC39A4 | solute carrier family 39 (zinc transporter), member 4 | −0.75 |
| GAS8 | growth arrest-specific 8 | −0.73 |
| SCAMP5 | secretory carrier membrane protein 5 | −0.72 |
| ERI3 | ERI1 exoribonuclease family member 3 | −0.72 |
| CARD16 | caspase recruitment domain family, member 16 | −0.71 |
| GLTPD1 | glycolipid transfer protein domain containing 1 | −0.69 |
| IFI30 | Interferon, gamma-inducible protein 30 | −0.69 |
| CASP5 | caspase 5, apoptosis-related cysteine peptidase | −0.68 |
| ME3 | malic enzyme 3, NADP(+)-dependent, mitochondrial | −0.64 |
| KCNB1 | potassium voltage-gated channel, Shab-related subfamily, member 1 | −0.64 |
| PPP4R1L | protein phosphatase 4, regulatory subunit 1-like | −0.64 |
| BCL2L2 | BCL2-like 2 | −0.56 |
| NKAIN1 | Na+/K+ transporting ATP ase interacting 1 | −0.55 |
| MAP3K3 | mitogen-activated protein kinase kinase kinase 3 | −0.49 |
| PRKACG | protein kinase, cAMP-dependent, catalytic, gamma | −0.47 |
| BOC | BOC cell adhesion-associated, oncogene regulated | −0.47 |
| PRKACA | protein kinase, cAMP-dependent, catalytic, alpha | −0.45 |
| MAPK3 | mitogen-activated protein kinase 3 | −0.42 |
| GRB2 | growth factor receptor-bound protein 2 | −0.40 |
Figure 8The expression patterns of microRNAs 378b and 378g at 3 and 60 μg/mL treatments in HCT116 and NCM460 cell lines. (a) Expression of microRNAs 378b; (b) Expression of microRNAs 378g. The experiments were carried out as in triplicate and data presented are in represent mean values. * indicates means p < 0.05, ** indicates means p < 0.01.